The changing of the guard: New CEOs move in

Recent months have seen a slew of management changes at major generics companies. Some of this has been driven by shareholder dissatisfaction with poor performance (Teva being the obvious example here), but there have also been generational and other shifts that offer interesting pointers...
Read More

Hartmut Retzlaff falls victim to barbarian hordes

The announcement today that Hartmut Retzlaff has stepped down as CEO of Stada ‘due to a serious long-term illness’ comes as something of a surprise, but the reasons are not hard to discern. For weeks, activist investors in the form of a group called...
Read More

Into the void: All change in UK generics in 2016

Teva’s announcement last year that it was to acquire Allergan’s generic assets (‘Actavis’), came as a total surprise to the market. All the more so since Teva was, at the time, in hot pursuit of Mylan. It was particularly startling news in the UK,...
Read More

Sandoz at the Novartis ‘Meet the Management’ event

Having agreed a major asset swap with GSK and hence simplified its business into three ‘powerhouse’ divisions, Novartis last week held its first ‘Meet the Management’ event for analysts and investors. This involved the top teams of each of the three divisions (and also...
Read More

Teva shoots the messenger – Jeremy Levin resigns

Teva announced last week that its CEO, Jeremy Levin, is to resign with immediate effect. This reportedly follows disagreements with the Teva Board over the implementation of the company’s strategy, as well as a slating from analysts and investors. Employees are also unhappy, after...
Read More

Here we go again: Pfizer sets up a new generics division

On July 29th, Pfizer announced that it would follow the lead set by GSK three months previously and divide up its business so as to create a separate unit containing its off-patent (i.e. generic) products. The new division, which is described as the Value...
Read More

Soul searchng at Teva as Dr Levin takes charge

At a hastily-arranged conference call a couple of weeks ago, the new CEO of Teva, Jeremy Levin, announced a downgrade of Teva’s forecast earnings for 2012 and talked a little about the business review that he is conducting and about his search for Teva’s...
Read More

New Year surprise as Teva brings in new CEO

The New Year has arrived with a bang, as Teva put out a press release on Jan 1st revealing that its CEO, Shlomo Yanai, is stepping down in May, to be replaced by Dr Jeremy Levin, a former executive with Bristol-Myers Squibb. Given that...
Read More